In numerous studies, researchers discovered that those administered SGLT2 inhibitors in the preliminary stages of diabetes or for long-term durations have physiologic and histological changes occurring in beta cells to alter insulin gene expression and sensitivity [24-26]. Here, SLC5A2 is linked to diabetes mellitus.